In 2023, hospital discharges for malignant neoplasm of the trachea, bronchus, and lung in France were recorded at around 45.10 thousand. Over the forecast period from 2024 to 2028, the discharge values are expected to rise slightly each year from 45.13 thousand in 2024 to 45.27 thousand in 2028. The year-on-year percentage variation indicates a steady increase, with minimal annual growth around 0.1%. The compound annual growth rate (CAGR) over five years points to a consistent, albeit modest, upward trend.

Future trends to watch for include:

Developments in early detection and screening programs that may affect discharge rates.
Innovations in treatment options potentially impacting hospitalization duration and frequency.
Evolving healthcare policies and their impact on cancer management and hospital discharge patterns.